机构：[1]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China[2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[3]Chinese Glioma Cooperative Group (CGCG), Beijing, China[4]China National Clinical Research Center for Neurological Diseases, Beijing, China[5]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China[6]Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
AimsTo investigate the role of LINC00152 in high-grade glioma (HGG). MethodsWe collected data from the Chinese Glioma Genome Atlas (CGGA) microarray, CGGA RNA sequencing, and GSE16011 datasets to evaluate the expression and prognostic relationship of LINC00152 in patients with HGGs. A knockdown assay was performed to determine the function of LINC00152 in glioma development and progression in vitro and in vivo. ResultsThe expression of LINC00152 was increased with glioma grade, especially in the mesenchymal TCGA subtype. LINC00152 was independently associated with poor prognosis, and the overall survival (OS) of the high expression group was shorter than the low expression group (median OS 14.77 vs 9.65months; P=0.0216) in the CGGA microarray dataset. The results were validated in the other 2 datasets. Based on the expression of LINC00152, 4288 (2519 positively; 1769 negatively) probes were extracted to perform a biological process analysis using the Database for Annotation, Visualization, and Integrated Discovery. Positively regulated genes were enriched in immune response, apoptotic process, cell adhesion, and regulation of cell proliferation. The clinical and molecular features of HGG patients indicated that patients in the LINC00152 high expression group tended to display the mesenchymal type, older (46years), isocitrate dehydrogenase1 wild-type, O(6)-methylguanine DNA methyltransferase unmethylated, nonchemotherapy, and low karnofsky performance status. Functionally, knockdown of LINC00152 inhibited cell proliferation, migration, and invasion and increased the sensitivity of chemotherapy in vitro. ConclusionOur results indicate that knockdown of LINC00152 could inhibit tumor growth in vivo. LINC00152 could serve as a potential prognostic biomarker in patients with HGG.
基金：
This work was supported by grants from
Ministry of Science and Technology of China
grant (2012CB825505, 2011BAI08B08);
Beijing Municipal Administration of
Hospitals’ Mission Plan (SML20150501);
“13th Five-Year Plan” National Science
and Technology supporting plan
(2015BAI09B04).
第一作者机构：[1]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China[2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[3]Chinese Glioma Cooperative Group (CGCG), Beijing, China[4]China National Clinical Research Center for Neurological Diseases, Beijing, China
通讯作者：
通讯机构：[*1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
推荐引用方式(GB/T 7714)：
Wen Wang,Fan Wu,Zheng Zhao,et al.Long noncoding RNA LINC00152 is a potential prognostic biomarker in patients with high-grade glioma[J].CNS NEUROSCIENCE & THERAPEUTICS.2018,24(10):957-966.doi:10.1111/cns.12850.
APA：
Wen Wang,Fan Wu,Zheng Zhao,Kuan-Yu Wang,Ruo-Yu Huang...&Ji-Zong Zhao.(2018).Long noncoding RNA LINC00152 is a potential prognostic biomarker in patients with high-grade glioma.CNS NEUROSCIENCE & THERAPEUTICS,24,(10)
MLA：
Wen Wang,et al."Long noncoding RNA LINC00152 is a potential prognostic biomarker in patients with high-grade glioma".CNS NEUROSCIENCE & THERAPEUTICS 24..10(2018):957-966
